Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pulmonology

Life After DAH: Survivorship and Monitoring

At a Glance

Recovering from Diffuse Alveolar Hemorrhage (DAH) requires long-term vigilance to prevent relapse. Patients typically undergo 18-24 months of maintenance therapy, frequent blood and lung monitoring, and must avoid triggers like vaping or certain blood-thinning medications.

Surviving the acute phase of Diffuse Alveolar Hemorrhage (DAH) is an incredible feat of resilience. As you transition from the hospital to home, the focus of your care will shift from emergency intervention to survivorship and vigilance [1]. While the threat of a relapse is a reality for many, especially those with autoimmune conditions, a structured monitoring plan can help you live a full life with confidence [2][3].

The Reality of Maintenance Therapy

If your DAH was caused by an autoimmune condition like ANCA-associated vasculitis (AAV) or Lupus (SLE), you will likely remain on maintenance therapy for a significant period [4][5]. This therapy is designed to keep your immune system from “waking up” and attacking your lungs again.

  • Common Medications: You may be prescribed medications such as Rituximab, Azathioprine, or Mycophenolate mofetil [6][5].
  • Duration: Maintenance therapy typically lasts for at least 18 to 24 months, and in many cases, doctors recommend extending it even longer to significantly reduce the risk of a relapse [7][8].
  • Living on Immunosuppressants: Living on these medications means making practical adjustments to prevent infections. You can still live a full life, but you should practice diligent hand hygiene, avoid crowded indoor spaces during severe cold and flu seasons, and stay away from visibly sick contacts [8][9].

The Recovery Timeline

It is important to manage your expectations regarding your energy levels. DAH causes both severe lung trauma and significant anemia. Because of this, it can take weeks or even months to stop feeling completely exhausted. Give your body the grace and time it needs to rebuild its red blood cell supply and heal the alveolar tissues [1][10].

Recognizing the Signs of Relapse

Because DAH can recur, you are the most important member of your monitoring team. A relapse can happen suddenly or develop slowly over several days [3][2]. You should contact your medical team immediately if you notice:

  • A return of shortness of breath (dyspnea), even if it is mild [11].
  • Coughing up blood or blood-tinged phlegm (hemoptysis) [12].
  • Sudden, extreme fatigue that doesn’t improve with rest [1].
  • Signs that your underlying disease is active, such as new joint pain, unexplained rashes, or persistent sinus congestion [2].

Your Surveillance Schedule

In the beginning, your monitoring will be frequent. Over time, as your condition stabilizes, the intervals between checks will lengthen. A typical schedule may include:

  1. Phase 1 (Months 1–6): Frequent blood work and urinalysis (every 2–4 weeks) to check kidney function and look for microscopic blood in the urine [13].
  2. Phase 2 (Months 6–24): Monitoring every 3 months, potentially including Pulmonary Function Tests (PFTs) to measure how well your lungs are moving oxygen [4].
  3. Phase 3 (Long-term): Periodic check-ups twice a year to ensure your maintenance medications are working and that there are no signs of “quiet” inflammation.

Protecting Your Lungs

To give your lungs the best chance at long-term health, it is essential to avoid known triggers that can damage the delicate alveolar-capillary membrane:

  • Vaping and E-cigarettes: Inhaling chemicals from vaping is a documented trigger for DAH and can cause severe lung injury [14][15].
  • Substance Use: Inhaled substances like cannabis or cocaine have been linked to the recurrence of pulmonary bleeding [16][17].
  • Medication Awareness: Always consult your specialist before starting new medications, especially anticoagulants (blood thinners) or NSAIDs like high-dose Ibuprofen, which can increase the risk of bleeding [18][19].

The Psychological Toll

Surviving a “medical emergency” like DAH can leave lasting psychological scars. Many patients experience scan anxiety (fear surrounding upcoming tests) or even symptoms of PTSD related to the trauma of being unable to breathe [20]. It is important to acknowledge these feelings and seek support through counseling or patient advocacy groups. Your mental health is just as critical to your recovery as your physical lung function.

Common questions in this guide

How long will I need to be on maintenance therapy after DAH?
If your diffuse alveolar hemorrhage was caused by an autoimmune condition, maintenance therapy typically lasts 18 to 24 months. Some doctors may recommend extending this time to significantly reduce the risk of a relapse.
What are the early warning signs of a DAH relapse?
Signs of a relapse include a return of shortness of breath, coughing up blood or blood-tinged phlegm, and sudden extreme fatigue. You might also notice symptoms of your underlying autoimmune disease returning, like new joint pain or sinus congestion.
How often do I need tests and scans after recovering from DAH?
In the first six months, you will likely need frequent blood work and urinalysis every two to four weeks. As your condition stabilizes, testing usually decreases to every three months, eventually spreading out to long-term check-ups twice a year.
Are there medications I should avoid after surviving DAH?
You should always consult your specialist before starting new medications. Blood thinners and nonsteroidal anti-inflammatory drugs like high-dose ibuprofen can increase the risk of bleeding and may need to be avoided.
Why am I still so tired weeks after my DAH treatment?
Diffuse alveolar hemorrhage causes severe lung trauma and significant anemia from blood loss. It is completely normal for it to take weeks or months to stop feeling exhausted as your body rebuilds its red blood cells and heals.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific maintenance schedule for my Rituximab or other immunosuppressants?
  2. 2.How frequently do I need to have blood and urine tests performed in the first year of recovery?
  3. 3.If I develop a common cold or flu, what steps should I take to ensure it doesn't trigger a DAH relapse?
  4. 4.Are there specific medications, like NSAIDs or blood thinners, that I must avoid permanently?
  5. 5.Who is the lead 'quarterback' of my long-term care—my rheumatologist or my pulmonologist?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Diffuse Alveolar Hemorrhage.

    Murray J, O'Brien S, Mitchell PD

    Seminars in respiratory and critical care medicine 2025; doi:10.1055/a-2725-7274.

    PMID: 41130281
  2. 2

    A Case of Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis Presenting With Diffuse Alveolar Hemorrhage and Renal Sparing.

    Alobaidi A, Albadry A, Murray A, Lytvak I

    Cureus 2023; (15(9)):e45397 doi:10.7759/cureus.45397.

    PMID: 37854734
  3. 3

    [Anti-neutrophil cytoplasmic antibodies-associated vasculitis with lung hemorrhage in the patient on maintenance haemodialysis: a case report].

    Ding JX, Wang M

    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2017; (49(5)):915-918.

    PMID: 29045980
  4. 4

    Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.

    Charles P, Perrodeau É, Samson M, et al.

    Annals of internal medicine 2020; (173(3)):179-187 doi:10.7326/M19-3827.

    PMID: 32479166
  5. 5

    Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses.

    Chen Y, Sun J, Zou K, et al.

    Rheumatology international 2017; (37(7)):1089-1099 doi:10.1007/s00296-017-3733-2.

    PMID: 28493175
  6. 6

    [Head-to-head studies on connective tissue diseases and vasculitides].

    Hellmich B, Mucke J, Aringer M

    Zeitschrift fur Rheumatologie 2024; (83(8)):620-628 doi:10.1007/s00393-024-01537-4.

    PMID: 39017966
  7. 7

    Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

    Karras A, Pagnoux C, Haubitz M, et al.

    Annals of the rheumatic diseases 2017; (76(10)):1662-1668 doi:10.1136/annrheumdis-2017-211123.

    PMID: 28546260
  8. 8

    Management of antineutrophil cytoplasmic antibody-associated vasculitis: a changing tide.

    Krishnan A, Walsh M, Collister D

    Current opinion in nephrology and hypertension 2023; (32(3)):278-283 doi:10.1097/MNH.0000000000000877.

    PMID: 36811629
  9. 9

    Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy-A meta-analysis.

    Pope V, Sivashanmugathas V, Moodley D, et al.

    Seminars in arthritis and rheumatism 2023; (60()):152189 doi:10.1016/j.semarthrit.2023.152189.

    PMID: 36931168
  10. 10

    [Clinicopathological diagnosis of diffuse alveolar hemorrhage].

    Fang F, Li YM, Hu ST, et al.

    Zhonghua yi xue za zhi 2016; (96(2)):108-12 doi:10.3760/cma.j.issn.0376-2491.2016.02.007.

    PMID: 26792692
  11. 11

    A 32-year-old man with hypoxemia and bilateral upper-lobe predominant ground-glass infiltrates on chest imaging.

    Helgeson SA, Heckman AJ, McCain JD, et al.

    Oxford medical case reports 2018; (2018(10)):omy072 doi:10.1093/omcr/omy072.

    PMID: 30302263
  12. 12

    [Diffuse alveolar hemorrhage - acute, life-threatening situation in rheumatology].

    Bradna P, Maňák J, Soukup T, et al.

    Vnitrni lekarstvi 2018; (64(2)):169-172.

    PMID: 29595282
  13. 13

    Pulmonary renal syndrome: a clinical review.

    Boyle N, O'Callaghan M, Ataya A, et al.

    Breathe (Sheffield, England) 2022; (18(4)):220208 doi:10.1183/20734735.0208-2022.

    PMID: 36865943
  14. 14

    Vaping and diffuse alveolar hemorrhage: All EVALI is not created equal.

    Hoekstra NE, Dannull KA, Weinman JP, et al.

    Pediatric pulmonology 2021; (56(12)):4057-4059 doi:10.1002/ppul.25675.

    PMID: 34551216
  15. 15

    Vaping-induced diffuse alveolar hemorrhage.

    Edmonds PJ, Copeland C, Conger A, Richmond BW

    Respiratory medicine case reports 2020; (29()):100996 doi:10.1016/j.rmcr.2020.100996.

    PMID: 31956478
  16. 16

    Cannabis-Induced Diffuse Alveolar Haemorrhage: A Case Report From the Intensive Care Unit.

    Condé Pinto N, Xavier R, Pereira M, et al.

    Cureus 2026; (18(1)):e101619 doi:10.7759/cureus.101619.

    PMID: 41694826
  17. 17

    Cannabis Smoking-induced Diffuse Alveolar Hemorrhage.

    Alqahtani A, Ammari Z, Ramahi A, et al.

    Cureus 2019; (11(7)):e5089 doi:10.7759/cureus.5089.

    PMID: 31511809
  18. 18

    Anticoagulant Use as an Independent Risk Factor and Higher In-Hospital Mortality in Patients Showing Alveolar Hemorrhage in Diffuse Lung Disease.

    Ugajin M, Kani H, Hattori H

    Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101094.

    PMID: 34684131
  19. 19

    Diffuse Alveolar Hemorrhage after Clopidogrel Use.

    Onuk T, İpek G, Karataş MB, et al.

    Balkan medical journal 2016; (33(6)):719-720 doi:10.5152/balkanmedj.2016.151545.

    PMID: 27994935
  20. 20

    Treatment of ANCA-Associated Glomerulonephritis Complicated by Bacteremia and Vertebral Osteomyelitis: A Challenging Medical Situation.

    Azrieh B, Thayyil A, Mudarres MF, et al.

    Case reports in nephrology 2025; (2025()):4392221 doi:10.1155/crin/4392221.

    PMID: 41133109

This page provides educational information on surviving and monitoring Diffuse Alveolar Hemorrhage. It does not replace professional medical advice from your pulmonologist or rheumatologist.

Get notified when new evidence is published on Diffuse alveolar hemorrhage.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.